US FDA declines approval of Eli Lilly and Incyte ’s baricitinib drug to treat RA
Eli Lilly and partner Incyte have announced that the US Food and Drug Administration (FDA) has declined to approve a new drug, baricitinib, to treat moderate-to-severe rheumatoid arthritis (RA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology